Hypothesis / aims of study
Recurrent urinary tract infections (rUTI) represent a significant public health burden, contributing to substantial healthcare costs, impaired quality of life, and increasing antimicrobial resistance. The gastrointestinal tract serves as a key reservoir for uropathogenic organisms. Modulation of the gut microbiome may influence UTI susceptibility. Fecal microbiota transplantation (FMT) is an established and highly effective therapy for recurrent, treatment-refractory Clostridioides difficile colitis. Emerging evidence has suggested a potential role for FMT in reducing rUTI frequency by depleting pathogenic bacterial reservoirs and promoting recolonization with commensal organisms associated with more favorable antimicrobial resistance profiles.
Study design, materials and methods
We performed a retrospective cohort study of women who underwent FMT for C difficile colitis between 2010 and 2025 at a single institution. Patients with a concomitant diagnosis of rUTI, defined by American Urological Association (AUA) guidelines, were included. The primary outcome was the number of symptomatic, culture-proven UTIs occurring within the two-year periods before and after FMT. Secondary outcomes included changes in antimicrobial resistance patterns, including the presence of vancomycin-resistant Enterococcus (VRE) on urine culture.
Interpretation of results
FMT was associated with a statistically significant reduction in rUTI frequency and elimination of VRE on subsequent urine cultures in female patients. Modulation of the gut microbiome may play a meaningful role in the prevention of rUTIs.